#United States #New York #Levi & Korsinsky #aTyr Pharma #ATYR

Levi & Korsinsky Calls for aTyr Pharma Investors to Take Action Before Deadline

Levi & Korsinsky, LLP, a law firm dedicated to shareholder rights, is alerting investors of aTyr Pharma, Inc. (NASDAQ: ATYR) regarding an important upcoming deadline related to a class action securities lawsuit. The firm warns that affected shareholders must act by December 8, 2025 to secure their rights and potentially recover losses from allegations of securities fraud.

Understanding the Lawsuit

This lawsuit centers on events that unfolded between November 7, 2024 and September 12, 2025. During this period, aTyr's management reportedly provided misleading positive statements about their drug, Efzofitimod, claiming it would facilitate full steroid tapering for patients. However, as stated in the complaint, there were significant discrepancies between these statements and the true efficacy of the drug, which became evident only after the company's investor call on September 15, 2025. On that date, aTyr reported that the EFZO-FIT study did not meet its primary endpoint, demonstrating serious flaws in the drug's anticipated results.

Following this revelation, aTyr’s stock plummeted from $6.03 a share to $1.02, a staggering decline of 83.2% in just one day, adversely impacting thousands of investors. The lawsuit seeks to represent those shareholders who relied on the company's misleading statements and incurred losses.

Next Steps for Investors

Investors who have suffered losses during the defined period have until December 8, 2025 to request the court to approve their designation as the lead plaintiff in the lawsuit. Notably, participating in the case does not necessitate that individuals take on the role of lead plaintiff, allowing for broader involvement in the quest for justice.

Those who have been impacted and wish to get involved are invited to contact Levi & Korsinsky directly. The firm emphasizes that joining the class action entails no financial burden, as members may be entitled to compensation without upfront costs or fees.

Why Choose Levi & Korsinsky?

With a proven track record in securities litigation spanning over two decades, Levi & Korsinsky has recovered hundreds of millions of dollars for shareholders in previous cases. The firm is recognized as one of the top securities litigation practices in the United States, according to the ISS Securities Class Action Services' Top 50 Report. Their experienced team, consisting of over seventy dedicated professionals, is well-equipped to navigate the complexities involved in such high-stakes legal situations.

For those compelled to act, further information can be found at the firm’s website or by contacting a representative directly via email or phone.

Contact Information

To learn more or participate, affected shareholders can reach out to:
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 17th Floor, New York, NY 10004
Email: [email protected]
Phone: (212) 363-7500

This is an important opportunity for investors in aTyr Pharma to take steps towards recovering their losses. If you are among those affected, don’t miss this critical deadline.

In the realm of securities fraud, knowledge is power, and timely action can make a profound difference.